MarketCap
Facebook
X
TelegramCleveland BioLabs, Inc. DSO Ratio 2011-2026 | CBLI
Annual DSO Ratio Cleveland BioLabs, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 16 | 124 | 80.8 | 104 | 36.6 | 85.1 | 26.3 | 19.7 | 4.28 | 72.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 | 4.28 | 56.9 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.01 | 3.79 % | $ 233 M |  USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.08 | 0.65 % | $ 7.41 B |  Australia |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 213.24 | 1.87 % | $ 5 B |  Danmark |
 |
BioDelivery Sciences International
BDSI
|
115 | - | -4.8 % | $ 255 M | USA |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M |  Canada |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.2 | 8.46 % | $ 435 M |  Israel |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 26.78 | -0.81 % | $ 1.3 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 9.61 | 0.63 % | $ 141 M | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 11.86 | 2.24 % | $ 781 M | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Certara
CERT
|
88.6 | $ 8.81 | -0.56 % | $ 1.41 B | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 27.16 | 2.76 % | $ 1.75 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Cellectis S.A.
CLLS
|
94.5 | $ 4.84 | 1.26 % | $ 116 M |  France |
 |
Axon Enterprise
AXON
|
134 | $ 567.93 | -0.73 % | $ 43 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
150 | $ 2.6 | 1.96 % | $ 16.3 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
ChromaDex Corporation
CDXC
|
13.2 | - | -0.88 % | $ 598 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.29 | -3.01 % | $ 730 M | USA |